Global Markets Direct’s, ‘Relapsing Remitting Multiple Sclerosis (RRMS) – Pipeline Review, H2 2015′, provides an overview of the Relapsing Remitting Multiple Sclerosis (RRMS)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• The report provides a snapshot of the global therapeutic landscape of Relapsing Remitting Multiple Sclerosis (RRMS)
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Relapsing Remitting Multiple Sclerosis (RRMS) and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Relapsing Remitting Multiple Sclerosis (RRMS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Relapsing Remitting Multiple Sclerosis (RRMS) pipeline on the basis of target, MoA, route of administration and molecule type
• Latest news and deals relating related to pipeline products

Reasons to buy

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Relapsing Remitting Multiple Sclerosis (RRMS)
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Relapsing Remitting Multiple Sclerosis (RRMS) pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Relapsing Remitting Multiple Sclerosis (RRMS) Overview 10
Therapeutics Development 11
Pipeline Products for Relapsing Remitting Multiple Sclerosis (RRMS) - Overview 11
Pipeline Products for Relapsing Remitting Multiple Sclerosis (RRMS) - Comparative Analysis 12
Relapsing Remitting Multiple Sclerosis (RRMS) - Therapeutics under Development by Companies 13
Relapsing Remitting Multiple Sclerosis (RRMS) - Therapeutics under Investigation by Universities/Institutes 17
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Relapsing Remitting Multiple Sclerosis (RRMS) - Products under Development by Companies 21
Relapsing Remitting Multiple Sclerosis (RRMS) - Products under Investigation by Universities/Institutes 24
Relapsing Remitting Multiple Sclerosis (RRMS) - Companies Involved in Therapeutics Development 25
AbbVie Inc. 25
Actelion Ltd 26
Allozyne, Inc. 27
Amarna Therapeutics B.V. 28
Antisense Therapeutics Limited 29
Biocon Limited 30
Biogen, Inc. 31
Cognosci, Inc. 32
F. Hoffmann-La Roche Ltd. 33
Forward Pharma A/S 34
Genmab A/S 35
GlaxoSmithKline Plc 36
Iltoo Pharma 37
Mapi Pharma Ltd. 38
MedImmune, LLC 39
Merck KGaA 40
Mitsubishi Tanabe Pharma Corporation 41
Neurotec Pharma SL 42
Novartis AG 43
Octapharma AG 44
Opexa Therapeutics, Inc. 45
RedHill Biopharma Ltd. 46
Sanofi 47
Synthetic Biologics, Inc. 48
Teva Pharmaceutical Industries Limited 49
Xenetic Biosciences plc 50
Zydus Cadila Healthcare Limited 51
Relapsing Remitting Multiple Sclerosis (RRMS) - Therapeutics Assessment 52
Assessment by Monotherapy Products 52
Assessment by Combination Products 53
Assessment by Target 54
Assessment by Mechanism of Action 57
Assessment by Route of Administration 60
Assessment by Molecule Type 62
Drug Profiles 64
(rifabutin + clarithromycin + clofazimine) - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
aldesleukin - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
amiselimod hydrochloride - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
ATL-1102 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
AZ-17 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Cell Therapy for Relapsing Remitting Multiple Sclerosis - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
cladribine - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
COG-133 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
daclizumab - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
diazoxide - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
dimethyl fumarate - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
estriol - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Gene Therapy for Relapsing and Remitting Multiple Sclerosis - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
glatiramer acetate ER - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
GSK-239512 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Guanabenz - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
HR-411 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
hydralazine - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
imilecleucel-t - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
immune globulin (human) - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
inebilizumab - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
interferon beta-1b - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
interferon beta-1b - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
itolizumab - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
laquinimod sodium - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
M-2736 - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
MyeloXen - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
ocrelizumab - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
ofatumumab - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
olesoxime - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
opicinumab - Drug Profile 122
Product Description 122
Mechanism of Action 122
R&D Progress 122
Pegylated Interferon-Beta-1b - Drug Profile 124
Product Description 124
Mechanism of Action 124
R&D Progress 124
ponesimod - Drug Profile 125
Product Description 125
Mechanism of Action 125
R&D Progress 125
siponimod - Drug Profile 127
Product Description 127
Mechanism of Action 127
R&D Progress 127
Small Molecule to Target CTLA4 and IFNGR for RRMS - Drug Profile 129
Product Description 129
Mechanism of Action 129
R&D Progress 129
vatelizumab - Drug Profile 130
Product Description 130
Mechanism of Action 130
R&D Progress 130
Relapsing Remitting Multiple Sclerosis (RRMS) - Recent Pipeline Updates 131
Relapsing Remitting Multiple Sclerosis (RRMS) - Dormant Projects 168
Relapsing Remitting Multiple Sclerosis (RRMS) - Discontinued Products 170
Relapsing Remitting Multiple Sclerosis (RRMS) - Product Development Milestones 171
Featured News & Press Releases 171
Oct 08, 2015: Results from ZINBRYTA (Daclizumab High-Yield Process) Phase 3 DECIDE Study Highlighting Efficacy Compared to Interferon Beta-1a Published in the New England Journal of Medicine and Presented at ECTRIMS 171
Oct 01, 2015: Biogen To Present Phase 3 Data On ZINBRYTA at ECTRIMS Congress 173
Jun 25, 2015: Teva and Active Biotech Announce Completion of Patient Enrollment in Laquinimod Phase III CONCERTO Trial 173
Jun 09, 2015: RedHill Biopharma Announces Completion of Patient Enrollment in the Phase IIa Study of RHB-104 for Multiple Sclerosis 174
Feb 26, 2015: Abbvie's Ongoing Research In Neuroscience And Oncology On ZINBRYTA Will Be Featured At The 2015 American Academy Of Neurology Annual Meeting 175
Dec 17, 2014: First Patient Treated in Mapi Pharma's Phase IIa Clinical Trial of GA Depot for Relapsing Remitting Multiple Sclerosis 176
Nov 04, 2014: Genzyme Announces Enrollment of First Patient in Phase II Vatelizumab Trial in Relapsing Remitting Multiple Sclerosis 177
Sep 12, 2014: Detailed Results from Biogen Idec and AbbVie's Pivotal Phase 3 Decide Study Further Define the Efficacy and Safety Profile of ZINBRYTA (Daclizumab High-Yield Process) 177
Sep 12, 2014: Teva Presents New Clinical Safety Data in RRMS Patients Treated with Laquinimod for Two or More Years at Joint ACTRIMS-ECTRIMS Meeting 179
Jul 31, 2014: Expanded Data on Disability and Cognitive Improvements in Phase II Study of Synthetic Biologics' Trimesta in Multiple Sclerosis to be Presented at 2014 Joint ACTRIMS-ECTRIMS Meeting 180
Appendix 181
Methodology 181
Coverage 181
Secondary Research 181
Primary Research 181
Expert Panel Validation 181
Contact Us 181
Disclaimer 182

List of Tables

Number of Products under Development for Relapsing Remitting Multiple Sclerosis (RRMS), H2 2015 11
Number of Products under Development for Relapsing Remitting Multiple Sclerosis (RRMS) - Comparative Analysis, H2 2015 12
Number of Products under Development by Companies, H2 2015 14
Number of Products under Development by Companies, H2 2015 (Contd..1) 15
Number of Products under Development by Companies, H2 2015 (Contd..2) 16
Number of Products under Investigation by Universities/Institutes, H2 2015 17
Comparative Analysis by Late Stage Development, H2 2015 18
Comparative Analysis by Clinical Stage Development, H2 2015 19
Comparative Analysis by Early Stage Development, H2 2015 20
Products under Development by Companies, H2 2015 21
Products under Development by Companies, H2 2015 (Contd..1) 22
Products under Development by Companies, H2 2015 (Contd..2) 23
Products under Investigation by Universities/Institutes, H2 2015 24
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by AbbVie Inc., H2 2015 25
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Actelion Ltd, H2 2015 26
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Allozyne, Inc., H2 2015 27
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Amarna Therapeutics B.V., H2 2015 28
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Antisense Therapeutics Limited, H2 2015 29
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Biocon Limited, H2 2015 30
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Biogen, Inc., H2 2015 31
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Cognosci, Inc., H2 2015 32
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 33
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Forward Pharma A/S, H2 2015 34
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Genmab A/S, H2 2015 35
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by GlaxoSmithKline Plc, H2 2015 36
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Iltoo Pharma, H2 2015 37
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Mapi Pharma Ltd., H2 2015 38
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by MedImmune, LLC, H2 2015 39
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Merck KGaA, H2 2015 40
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2015 41
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Neurotec Pharma SL, H2 2015 42
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Novartis AG, H2 2015 43
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Octapharma AG, H2 2015 44
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Opexa Therapeutics, Inc., H2 2015 45
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by RedHill Biopharma Ltd., H2 2015 46
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Sanofi, H2 2015 47
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Synthetic Biologics, Inc., H2 2015 48
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015 49
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Xenetic Biosciences plc, H2 2015 50
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Zydus Cadila Healthcare Limited, H2 2015 51
Assessment by Monotherapy Products, H2 2015 52
Assessment by Combination Products, H2 2015 53
Number of Products by Stage and Target, H2 2015 55
Number of Products by Stage and Mechanism of Action, H2 2015 58
Number of Products by Stage and Route of Administration, H2 2015 61
Number of Products by Stage and Molecule Type, H2 2015 63
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics - Recent Pipeline Updates, H2 2015 131
Relapsing Remitting Multiple Sclerosis (RRMS) - Dormant Projects, H2 2015 168
Relapsing Remitting Multiple Sclerosis (RRMS) - Dormant Projects (Contd..1), H2 2015 169
Relapsing Remitting Multiple Sclerosis (RRMS) - Discontinued Products, H2 2015 170

List of Figures

Number of Products under Development for Relapsing Remitting Multiple Sclerosis (RRMS), H2 2015 11
Number of Products under Development for Relapsing Remitting Multiple Sclerosis (RRMS) - Comparative Analysis, H2 2015 12
Number of Products under Development by Companies, H2 2015 13
Number of Products under Investigation by Universities/Institutes, H2 2015 17
Comparative Analysis by Late Stage Development, H2 2015 18
Comparative Analysis by Clinical Stage Development, H2 2015 19
Comparative Analysis by Early Stage Products, H2 2015 20
Assessment by Monotherapy Products, H2 2015 52
Number of Products by Top 10 Targets, H2 2015 54
Number of Products by Stage and Top 10 Targets, H2 2015 54
Number of Products by Top 10 Mechanism of Actions, H2 2015 57
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 57
Number of Products by Routes of Administration, H2 2015 60
Number of Products by Stage and Routes of Administration, H2 2015 60
Number of Products by Top 10 Molecule Types, H2 2015 62
Number of Products by Stage and Top 10 Molecule Types, H2 2015 62